The US Department of Defense is developing a plan to screen active-duty military personnel for low testosterone, according to a July 2026 announcement. This initiative could significantly expand the patient population for testosterone replacement therapy and reshape the market dynamics for pharmaceutical manufacturers. The market for testosterone therapies is currently valued at approximately $1.8 billion annually. The military's plan introduces a new, large-scale driver for a sector that has faced scrutiny over long-term cardiovascular risks and off-label use.
Context — why this matters now
The US military's focus on service member wellness has intensified following the 2024 National Defense Authorization Act, which mandated improvements in servicemember health readiness. Military demographics skew heavily toward the age groups most commonly associated with testosterone decline, creating a large potential patient pool. The initiative emerges as the Pentagon addresses recruitment and retention challenges, with medical readiness being a key factor in troop eligibility.
Regulatory scrutiny of testosterone products peaked a decade ago when the FDA required manufacturers to add warning labels about potential heart attack and stroke risks in 2015. That action followed a sharp decline in prescriptions after studies questioned the therapies' safety. The current military review represents a potential rehabilitation of TRT's medical standing if adopted for a physically demanding, high-stakes profession.
Recent clinical research has provided a more nuanced view of TRT risks and benefits. A 2023 meta-analysis in The Lancet Healthy Longevity found that for men with clinically diagnosed hypogonadism, therapy improved body composition and metabolic health without significantly increasing cardiovascular events. This evolving evidence base may be influencing the military's risk-benefit calculus.
Data — what the numbers show
The global testosterone replacement therapy market was valued at $1.78 billion in 2025. Analysts project it will grow to $2.65 billion by 2030, representing a compound annual growth rate of 8.3%. The US military's active-duty population totals over 1.3 million personnel, predominantly male. A screening program could identify hundreds of thousands of potential new patients.
Market leadership is concentrated among a few key players. AbbVie's AndroGel, a topical gel, holds the largest market share at approximately 35%. Pfizer and Endo International are other significant participants with injectable and other formulations. The S&P 500 Pharmaceuticals Industry Index has returned 4.2% year-to-date, slightly underperforming the broader S&P 500's 5.1% gain.
Prescription volumes have shown volatility over the past decade. Testosterone product prescriptions peaked at over 6.5 million annually in the US before the 2015 FDA safety warnings. Volumes subsequently fell to around 4 million but have been gradually recovering, reaching 4.8 million prescriptions in 2025. The military initiative could add a stable, institutional demand source less sensitive to consumer advertising fluctuations.
| Metric | Current (2025) | Post-Military Screening (Potential) | Change |
|---|
| Annual Market Size | $1.78B | $2.1B - $2.4B | +18% to +35% |
| US Prescription Volume | 4.8M | 5.5M - 6.5M | +15% to +35% |
| AbbVie Market Share | 35% | 30% - 38% | Competitive Pressure |
Analysis — what it means for markets / sectors / tickers
The primary beneficiaries of this development are the dominant TRT manufacturers. AbbVie (ABBV) stands to gain the most from any market expansion due to its leading position with AndroGel. Pfizer (PFE) and its subsidiary Hospira, a major producer of injectable testosterone, would also see elevated demand. Medical diagnostics firms like Quest Diagnostics (DGX) and Laboratory Corporation of America (LH) would experience increased volume from the required blood testing.
A key risk to this bullish thesis is that the military's final protocol may be highly conservative. Eligibility could be restricted to service members with the most severe deficiencies, limiting the addressable population. Insurance coverage and cost-effectiveness analyses will also determine the program's ultimate scale. Generic competition could capture a disproportionate share of any new demand, pressuring branded product margins.
Institutional positioning in pharmaceutical equities has been neutral to slightly bearish in recent quarters. Hedge fund net exposure to the sector is near a five-year low. Positive news flow from a large, predictable buyer like the US military could trigger a reassessment of growth projections for affected companies. Flow data indicates modest buying interest in large-cap pharma ETFs like XLV following the announcement.
Outlook — what to watch next
The Pentagon's Health Agency is expected to release its final TRT screening and treatment protocol by the fourth quarter of 2026. This document will define the clinical thresholds for diagnosis and the approved treatment modalities, directly impacting which companies benefit. The implementation timeline for base-level screening will be a critical indicator of near-term revenue potential.
Investors should monitor prescription tracking data from entities like IQVIA for early signs of demand acceleration. AbbVie's next earnings call on October 27, 2026, may provide management commentary on military-related opportunities. Key resistance for the XLV ETF sits at $152, a level it has tested and failed to breach twice in the past year. A breakout above this level on high volume would signal strong institutional conviction in the sector.
The 2027 National Defense Authorization Act legislative process will be a catalyst. Congressional appropriation and specific language regarding TRT funding will determine the program's longevity. If the program is successfully implemented, other federal agencies with large workforces, such as the Department of Homeland Security, could consider similar initiatives, creating a broader public sector trend.
Frequently Asked Questions
How does testosterone replacement therapy work?
Testosterone replacement therapy compensates for low natural hormone production through external administration. Common methods include daily topical gels, bi-weekly or monthly injections, and subcutaneous pellets that release testosterone over several months. These treatments aim to restore serum testosterone levels to a normal physiological range, typically above 300 nanograms per deciliter. Therapy requires ongoing monitoring through blood tests to adjust dosage and minimize side effects.
What are the main financial risks for TRT manufacturers?
The primary financial risk remains product liability litigation related to cardiovascular events. AbbVie has settled thousands of lawsuits concerning AndroGel, with charges impacting earnings. Patent expirations for branded products invite increased generic competition, which erodes pricing power. Regulatory changes, such as stricter FDA prescribing guidelines or Medicare reimbursement cuts, could also suddenly constrict the addressable market and reduce profitability.
Which other healthcare sectors could be affected by expanded TRT use?
